🔗 Share this article

While the United States undertakes sweeping adjustments to its immunization recommendations, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning Covid vaccinations during the pandemic and has zeroed in on possible fatalities following COVID-19 vaccination in her recent tenure at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities were set to announce major changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US at odds with a large portion of the world with no evidence for public health gain. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

Consolidating Power at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending some pediatric shot schedules in the US so as to align more similar to the Danish model, a nation with universal health coverage and a population roughly the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

The appointee has no apparent track record in drug development, regulation or management, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Past directors of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

This division has an enormous workload at the FDA, she emphasized.

“Everybody just pays attention on the new drug program, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and every single one must be managed,” she explained. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the job, which manages in excess of 5,000 employees. “It is a massive administrative position, if you do it right,” the former official said.

Agency Reaction and Controversial Programs

In response to questions about Høeg’s fitness for the role and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a representative said that the “inquiries stem from inaccurate presumptions”.

“Her resume matches the duties of her role,” the official said, noting the time Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's new fast-track approval initiative, a disputed expedited medication authorization process that apparently worried her former heads. “How are these therapies being chosen for this voucher program? Who makes the choices?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Overall, he remarked, “the agency seems to be moving towards laxer rules of most medications, except for vaccines.”

Documented History on Vaccines

With immunizations, Dr. Høeg has a clearer, if problematic, track record, Howard observe. She released a study using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming administration encompassed changing rules for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a podcast. At the agency, Høeg has reportedly proposed barring teenage boys from obtaining Covid vaccinations.

“She is an thorough true believer who commences with her conclusions and works backwards to accommodate the evidence in a very disingenuous, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow dissenters, {like|